First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

June 14, 2027

Study Completion Date

May 24, 2031

Conditions
Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Interventions
DRUG

225Ac-PSMA-Trillium (BAY3563254)

Intravenous slow injection on Day 1 of a 6 week treatment cycle.

Trial Locations (33)

1070

RECRUITING

Institut Jules Bordet / Nuclear Medicine, Anderlecht

3000

NOT_YET_RECRUITING

UZ Leuven - Campus Gasthuisberg - Nuclear Medicine, Leuven

4056

NOT_YET_RECRUITING

Universitätsspital Basel, Basel

5404

NOT_YET_RECRUITING

Kantonsspital Baden, Baden

8091

NOT_YET_RECRUITING

Univestitätsspital Zürich (USZ), Zurich

8500

RECRUITING

AZ Groeninge Campus Kennedylaan - Urology, Kortrijk

17176

NOT_YET_RECRUITING

Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC, Stockholm

20141

NOT_YET_RECRUITING

Istituto Europeo di Oncologia s.r.l - Medicina Nucleare, Milan

20520

SUSPENDED

Turku University Hospital, Turku

22185

NOT_YET_RECRUITING

Skånes Universitetssjukhus Lund - Onkologens kliniska forskningsenhet, Lund

33520

SUSPENDED

Tampere University Hospital, Tampere

41346

NOT_YET_RECRUITING

Sahlgrenska Universitetssjukhuset - Klinisk prövningsenhet Fas I/FIH, Gothenburg

55455

NOT_YET_RECRUITING

M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center, Minneapolis

68130

NOT_YET_RECRUITING

XCancer Omaha, Omaha

70210

SUSPENDED

Kuopio University Hospital, Kuopio

75185

SUSPENDED

Akademiska Sjukhuset - Fas-I-enheten, Uppsala

77030

NOT_YET_RECRUITING

The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston

80131

NOT_YET_RECRUITING

IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica, Napoli

91010

NOT_YET_RECRUITING

City of Hope - Duarte Cancer Center, Duarte

T6G 1Z2

SUSPENDED

Cross Cancer Institute, Clinical Trials Unit, Edmonton

V5Z 4E6

RECRUITING

BC Cancer - Vancouver Site, Vancouver

L8V 5C2

RECRUITING

Juravinski Cancer Centre - Clinical Trials Department, Hamilton

M5G 2C4

NOT_YET_RECRUITING

Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology, Toronto

H2X 3E4

RECRUITING

Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi, Montreal

H4A 3J1

RECRUITING

McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM), Montreal

J1H 5N4

RECRUITING

Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont, Sherbrooke

FIN-00029

NOT_YET_RECRUITING

Helsinki University Hospital, Comprehensive Cancer Center, Helsinki

FIN-00180

SUSPENDED

Docrates Mehiläinen Syöpäsairaala, Helsinki

9713 GZ

NOT_YET_RECRUITING

Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center, Groningen

3015 CE

NOT_YET_RECRUITING

Erasmus Medisch Centrum, Rotterdam

Surrey

RECRUITING

"The Royal Marsden NHS Foundation Trust , Sutton - Oak Foundation Drug Development Unit"

Unknown

RECRUITING

"University College London Hospitals NHS Foundation Trust , University College Hospital - NIHR UCLH Clinical Research Facility"

NOT_YET_RECRUITING

"The Newcastle upon Tyne Hospitals NHS Foundation Trust , Freeman Hospital - Cancer Trials Research Centre"

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06217822 - First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter